{
    "clinical_study": {
        "@rank": "149584", 
        "arm_group": {
            "arm_group_label": "Sulbactam Sodium (SBT) and Ampicillin Sodium (ABPC) Powder", 
            "description": "Patients with the following disease who received high doses of UNASYN (exceeding 6 g per day) from the first dosing date or the second dosing date: Pneumonia, Lung Abscess, Peritonitis."
        }, 
        "brief_summary": {
            "textblock": "The purpose of the survey is to study the followings under practical use, regarding the\n      safety and effectiveness in high-dose administration (exceeding 6 g per day) of UNASYN-S and\n      UNASYN-S KIT for intravenous use (UNASYN).\n\n        1. Adverse Drug Reaction(s) that cannot be expected from precautions (Unexpected Adverse\n           Drug Reaction)\n\n        2. Incidence status of adverse drug reactions\n\n        3. Factors that may affect the safety and effectiveness"
        }, 
        "brief_title": "Drug Use Investigation Of Sulbactam/Ampicillin (UNASYN) 12g (Regulatory Post Marketing Commitment Plan)", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pneumonia", 
            "Lung Abscess", 
            "Peritonitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Abscess", 
                "Lung Abscess", 
                "Peritonitis", 
                "Pneumonia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Implemented as a Special Investigation by a central registration system"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with the following disease who received high doses of UNASYN (exceeding 6 g\n             per day) from the first dosing date or the second dosing date. 1) Pneumonia, 2) Lung\n             Abscess, 3) Peritonitis\n\n          -  Patients aged 15 years or olde\n\n        Exclusion Criteria:\n\n          -  Patients with the following disease who received high doses of UNASYN (less than 6 g\n             per day) from the first dosing date or the second dosing date. 1) Pneumonia, 2) Lung\n             Abscess, 3) Peritonitis\n\n          -  Patients aged less than 15 years."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "15 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with the following disease who received high doses of UNASYN (exceeding 6 g per\n        day) from the first dosing date or the second dosing date.\n\n          1. Pneumonia\n\n          2. Lung Abscess\n\n          3. Peritonitis"
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01793688", 
            "org_study_id": "A9231002"
        }, 
        "intervention": {
            "arm_group_label": "Sulbactam Sodium (SBT) and Ampicillin Sodium (ABPC) Powder", 
            "description": "Intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection or drip infusion. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency)).\nKit for intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection after dissolved in an accompanying reconstitution diluent. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency)).", 
            "intervention_name": "Sulbactam Sodium (SBT)/Ampicillin Sodium (ABPC)", 
            "intervention_type": "Drug", 
            "other_name": "UNASYN-S"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Ampicillin", 
                "Sulbactam", 
                "Sultamicillin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "UNASYN-S", 
            "High Dose"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A9231002&StudyName=Drug%20Use%20Investigation%20Of%20Sulbactam/Ampicillin%20%28UNASYN%29%2012g%20%28Regulatory%20Post%20Marketing%20Commitment%20Plan%29"
        }, 
        "number_of_groups": "1", 
        "official_title": "Drug Use Investigation Of Sulbactam/Ampicillin 12g", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of Participants With Clinical Benefit", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01793688"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "C-Reactive Protein (CRP)", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}